Repatha study shows cholesterol reduction for Type 2 diabetes patients


Amgen announced the release of new data from a phase 3 study June 23 that showed its cholesterol drug Repatha reduced two key types of cholesterol by more than 50 percent in patients with Type 2 diabetes. Presented at the American Diabetes Association annual meeting, the study - dubbed Banting by the Thousand Oaks biotech giant - evaluated Repatha on a monthly dosing schedule.



from Biotech News